Literature DB >> 6734044

Effect of food on blood hydralazine levels and response in hypertension.

A M Shepherd, N A Irvine, T M Ludden.   

Abstract

A study with a nonspecific hydralazine assay reported that food increased hydralazine concentrations in plasma. We used a specific HPLC hydralazine assay to determine the effect of food on hydralazine blood levels and hemodynamic responses after oral hydralazine. Six subjects with uncomplicated essential hypertension were given 1 mg/kg hydralazine solution orally on two occasions at least 3 days apart. On 1 study day subjects fasted and on the other they were given a standard meal 45 min before hydralazine. Mean arterial pressure and heart rate were monitored for 2 hr before and for 4 hr after hydralazine and frequent venous blood samples were drawn for hydralazine assay. Hepatic blood flow was estimated by determination of indocyanine green clearance before food, after food, and 30 min after hydralazine. Peak blood hydralazine concentrations fell in all (46.2% +/- 11.5%; means +/- SE) and areas under the blood hydralazine concentration/time curves fell (45.7% +/- 9.5%) after food. This could not be explained by changes in liver blood flow. Food-related reductions in blood levels of hydralazine were associated with reduced vasodepressor effects (41.5% +/- 5.6%). It is possible that food increases intravascular conversion of hydralazine to hydralazine pyruvic acid hydrazone. The reduction in vasodepressor response suggests that patients with hypertension should take hydralazine at a fixed time in relation to meals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734044     DOI: 10.1038/clpt.1984.131

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 3.  The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-11-02

Review 4.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

5.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

6.  Verapamil pharmacokinetics and apparent hepatic and renal blood flow.

Authors:  P A Meredith; H L Elliott; F Pasanisi; A W Kelman; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 7.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

8.  Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

Authors:  H A Semple; Y K Tam; R T Coutts
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

Review 9.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.

Authors:  J Kindler; P C Rüegg; M Neuray; W Pacha
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.